137 related articles for article (PubMed ID: 9303196)
1. The design of antisense RNA.
Sczakiel G
Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):439-44. PubMed ID: 9303196
[TBL] [Abstract][Full Text] [Related]
2. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
Kronenwett R; Haas R; Sczakiel G
J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
[TBL] [Abstract][Full Text] [Related]
3. Natural antisense RNA/target RNA interactions: possible models for antisense oligonucleotide drug design.
Delihas N; Rokita SE; Zheng P
Nat Biotechnol; 1997 Aug; 15(8):751-3. PubMed ID: 9255788
[TBL] [Abstract][Full Text] [Related]
4. Implications of RNA structure on the annealing of a potent antisense RNA directed against the human immunodeficiency virus type 1.
Eckardt S; Romby P; Sczakiel G
Biochemistry; 1997 Oct; 36(42):12711-21. PubMed ID: 9335527
[TBL] [Abstract][Full Text] [Related]
5. Length dependence of RNA-RNA annealing.
Patzel V; Sczakiel G
J Mol Biol; 1999 Dec; 294(5):1127-34. PubMed ID: 10600371
[TBL] [Abstract][Full Text] [Related]
6. Theoretical design of antisense genes with statistically increased efficacy.
Lehmann MJ; Patzel V; Sczakiel G
Nucleic Acids Res; 2000 Jul; 28(13):2597-604. PubMed ID: 10871411
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 TAR as anchoring site for optimized catalytic RNAs.
Puerta-Fernandez E; Barroso-del Jesus A; Romero-López C; Berzal-Herranz A
Biol Chem; 2003 Mar; 384(3):343-50. PubMed ID: 12715885
[TBL] [Abstract][Full Text] [Related]
8. Hammerhead ribozymes: biochemical and chemical considerations.
Goodchild J
Curr Opin Mol Ther; 2000 Jun; 2(3):272-81. PubMed ID: 11249621
[TBL] [Abstract][Full Text] [Related]
9. Towards a new concept of gene inactivation: specific RNA cleavage by endogenous ribonuclease P.
Hartmann RK; Krupp G; Hardt WD
Biotechnol Annu Rev; 1995; 1():215-65. PubMed ID: 9704090
[TBL] [Abstract][Full Text] [Related]
10. Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells.
Patzel V; Sczakiel G
Nat Biotechnol; 1998 Jan; 16(1):64-8. PubMed ID: 9447596
[TBL] [Abstract][Full Text] [Related]
11. In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1.
Rittner K; Burmester C; Sczakiel G
Nucleic Acids Res; 1993 Mar; 21(6):1381-7. PubMed ID: 8464728
[TBL] [Abstract][Full Text] [Related]
12. Theoretical and experimental selection parameters for HBV-directed antisense RNA are related to increased RNA-RNA annealing.
Patzel V; zu Putlitz J; Wieland S; Blum HE; Sczakiel G
Biol Chem; 1997 Jun; 378(6):539-43. PubMed ID: 9224935
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of infectious human immunodeficiency virus type 1 virions via lentiviral vector encoded short antisense RNAs.
Gu S; Ji J; Kim JD; Yee JK; Rossi JJ
Oligonucleotides; 2006; 16(4):287-95. PubMed ID: 17155905
[TBL] [Abstract][Full Text] [Related]
14. Hairpin antisense oligonucleotides containing 2'-methoxynucleosides with base-pairing in the stem region at the 3'-end: penetration, localization, and Anti-HIV activity.
Kuwasaki T; Hosono K; Takai K; Ushijima K; Nakashima H; Saito T; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1996 Nov; 228(2):623-31. PubMed ID: 8920960
[TBL] [Abstract][Full Text] [Related]
15. The role of target accessibility for antisense inhibition.
Sczakiel G; Far RK
Curr Opin Mol Ther; 2002 Apr; 4(2):149-53. PubMed ID: 12044036
[TBL] [Abstract][Full Text] [Related]
16. Length variation of helix III in a hammerhead ribozyme and its influence on cleavage activity.
Hammann C; Martinez E; Moosbauer J; Hormes R; Tabler M
Antisense Nucleic Acid Drug Dev; 1999 Feb; 9(1):25-31. PubMed ID: 10192286
[TBL] [Abstract][Full Text] [Related]
17. Complementary large loops determine the rate of RNA duplex formation in vitro in the case of an effective antisense RNA directed against the human immunodeficiency virus type 1.
Homann M; Rittner K; Sczakiel G
J Mol Biol; 1993 Sep; 233(1):7-15. PubMed ID: 8377194
[TBL] [Abstract][Full Text] [Related]
18. Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies.
Jen KY; Gewirtz AM
Stem Cells; 2000; 18(5):307-19. PubMed ID: 11007915
[TBL] [Abstract][Full Text] [Related]
19. Antisense binding enhanced by tertiary interactions: binding of phosphorothioate and N3'-->P5' phosphoramidate hexanucleotides to the catalytic core of a group I ribozyme from the mammalian pathogen Pneumocystis carinii.
Testa SM; Gryaznov SM; Turner DH
Biochemistry; 1998 Jun; 37(26):9379-85. PubMed ID: 9649319
[TBL] [Abstract][Full Text] [Related]
20. Identifying accessible sites in RNA: the first step in designing antisense reagents.
Pan WH; Clawson GA
Curr Med Chem; 2006; 13(25):3083-103. PubMed ID: 17073649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
